Who are Amgen's decision-makers?
Amgen is led by Robert A. Bradway. Sellers should map decisions across the executive sponsor, business-unit owner, procurement, legal, security, privacy, compliance, finance, clinical or scientific stakeholders, and implementation owners.
- CEO
- Robert A. Bradway
- CFO/key exec
- Peter H. Griffith
- Founded
- 1980
- Employees
- 28,000+
- HQ
- Thousand Oaks, CA
- Status
- Nasdaq: AMGN
- Robert A. BradwayChairman and Chief Executive OfficerCEO since 2012Leads Amgen's global therapeutics portfolio and capital strategy.
- Peter H. GriffithExecutive Vice President and Chief Financial OfficerCFO since 2020Oversees financial operations and investor planning.
- Paul BurtonSenior Vice President and Chief Medical OfficerCMO since 2023Guides clinical and medical strategy.
- Murdo GordonExecutive Vice President, Global Commercial OperationsCommercial leader since 2022Runs global commercial execution and market access.
Who leads Amgen?
Amgen's leadership team combines enterprise healthcare operations, finance, R&D, clinical, product, technology, legal, manufacturing, and commercial roles. The CEO and CFO set capital priorities, while business-unit leaders decide which operational problems become funded initiatives.
Who actually makes buying decisions at Amgen?
Buying decisions usually start with a business-unit sponsor, then move through procurement, finance, legal, information security, privacy, compliance, quality, and implementation owners. Clinical, reimbursement, regulatory, or scientific stakeholders become essential whenever the purchase touches patient care, regulated data, clinical evidence, medical products, lab workflows, or payer/provider economics.
How is Amgen organized as it scales?
Amgen operates through product, therapeutic-area, regional, manufacturing, commercial, and corporate functions. That creates multiple entry points, but enterprise standards for security, privacy, compliance, contracting, vendor risk, and data governance can still control the final approval path.
As of June 2026.Sources:Amgen leadershipAmgen annual reports
Amgen — frequently asked questions
